Sengenics Brings Best-of-Breed UK Genetic Test to Asia for Definitive Diagnosis of Children's Disorders
Kuala Lumpur, Malaysia, July 26, 2011 --(PR.com)-- Sengenics today announced the introduction of a new microarray based genetic diagnostics test into Asia. The microarray used for the test was designed by Oxford Gene Technology (OGT), UK in conjunction with Emory Genetics, USA.
Microarrays are now recommended as the most effective method for diagnosing children's disorders. This was published in a recent consensus statement by leading international medical institutions in the American Journal of Human Genetics. Using microarrays results in a more than 600% increase in diagnostic yield when compared to conventional tests.
Johan Poole-Johnson, Director of Sengenics commented, “Ease of interpretation and accuracy are critical in diagnosis, the OGT designed array gives us all of these critical benefits.” Among those adopting the platform are Children's Hospital Boston (an affiliate of Harvard Medical School), Emory Genetics USA, Sick Kids’ Hospital in Toronto and the UK National Health Service (NHS) National Genetics Reference Laboratory. These institutions chose the OGT array due to its outstanding accuracy and high-definition clarity. These qualities are critical in the field of diagnostics especially for detecting learning and developmental disorders in children.
There are 3 key tests available from Sengenics; Learning Disorders and Autism, Physical Disorders such as Duchenne Muscular Dystrophy as well as a Whole Genome test. There are also new tests for Metabolic Disorders as well as Inherited Cancers. All tests will be run in Sengenics' state-of-the-art laboratory in Malaysia. The lab is the first in Asia modelled on best-of breed methods and processes optimised by leading diagnostics facilities in the UK and USA. All Sengenics laboratory staff have been trained by experts in the UK NHS.
Early Intervention in Children’s Developmental Disorders:
According to a new study published in the Journal “Pediatrics” from the U.S. Centers for Disease Control and Prevention, one in 6 children have a developmental disability such as Autism, learning disorders or Attention-Deficit/Hyperactivity Disorder (ADHD).
Without an accurate, definitive diagnosis the medical professionals have a dilemma. Currently, they can pass on the “bad news” of their suspicions, but can then only recommend waiting for further symptoms to manifest in order to judge what intervention should be initiated.
Now with this new service from Sengenics, doctors have a valuable and definitive diagnostic tool that will identify with accuracy and clarity what the genetic disorder is. This allows doctors and specialists to recommend, at a very early stage, remedial steps to treat or manage the disorder. Even with ‘incurable’ disorders such as Autism, the earlier the intervention, the greater the benefits for both the child and the care-giver.
In recognition of the importance of targeted intervention, Sengenics will also be supporting medical professionals and affected families by providing access to the latest information on disorder management and treatment options via the company’s international network of resources, and support group contacts.
About Sengenics:
Sengenics offers molecular diagnostics and research services to the medical community and community throughout Asia. Sengenics is the exclusive strategic partner of Oxford Gene Technology (OGT) for Asia. OGT was founded by the world-famous scientist Professor Sir Edwin Southern of Oxford University, the inventor of the Southern Blot. OGT is also the holder of the fundamental patents underlying microarrays.
The core focus of Sengenics is to increase the breadth and sensitivity of diagnostics, based on microarrays and new genomics technologies, whilst reducing the cost and time required in producing reliable and accurate results.
For more information about Sengenics, please visit our website at www.sengenics.com or email enquiries@sengenics.com
###
Microarrays are now recommended as the most effective method for diagnosing children's disorders. This was published in a recent consensus statement by leading international medical institutions in the American Journal of Human Genetics. Using microarrays results in a more than 600% increase in diagnostic yield when compared to conventional tests.
Johan Poole-Johnson, Director of Sengenics commented, “Ease of interpretation and accuracy are critical in diagnosis, the OGT designed array gives us all of these critical benefits.” Among those adopting the platform are Children's Hospital Boston (an affiliate of Harvard Medical School), Emory Genetics USA, Sick Kids’ Hospital in Toronto and the UK National Health Service (NHS) National Genetics Reference Laboratory. These institutions chose the OGT array due to its outstanding accuracy and high-definition clarity. These qualities are critical in the field of diagnostics especially for detecting learning and developmental disorders in children.
There are 3 key tests available from Sengenics; Learning Disorders and Autism, Physical Disorders such as Duchenne Muscular Dystrophy as well as a Whole Genome test. There are also new tests for Metabolic Disorders as well as Inherited Cancers. All tests will be run in Sengenics' state-of-the-art laboratory in Malaysia. The lab is the first in Asia modelled on best-of breed methods and processes optimised by leading diagnostics facilities in the UK and USA. All Sengenics laboratory staff have been trained by experts in the UK NHS.
Early Intervention in Children’s Developmental Disorders:
According to a new study published in the Journal “Pediatrics” from the U.S. Centers for Disease Control and Prevention, one in 6 children have a developmental disability such as Autism, learning disorders or Attention-Deficit/Hyperactivity Disorder (ADHD).
Without an accurate, definitive diagnosis the medical professionals have a dilemma. Currently, they can pass on the “bad news” of their suspicions, but can then only recommend waiting for further symptoms to manifest in order to judge what intervention should be initiated.
Now with this new service from Sengenics, doctors have a valuable and definitive diagnostic tool that will identify with accuracy and clarity what the genetic disorder is. This allows doctors and specialists to recommend, at a very early stage, remedial steps to treat or manage the disorder. Even with ‘incurable’ disorders such as Autism, the earlier the intervention, the greater the benefits for both the child and the care-giver.
In recognition of the importance of targeted intervention, Sengenics will also be supporting medical professionals and affected families by providing access to the latest information on disorder management and treatment options via the company’s international network of resources, and support group contacts.
About Sengenics:
Sengenics offers molecular diagnostics and research services to the medical community and community throughout Asia. Sengenics is the exclusive strategic partner of Oxford Gene Technology (OGT) for Asia. OGT was founded by the world-famous scientist Professor Sir Edwin Southern of Oxford University, the inventor of the Southern Blot. OGT is also the holder of the fundamental patents underlying microarrays.
The core focus of Sengenics is to increase the breadth and sensitivity of diagnostics, based on microarrays and new genomics technologies, whilst reducing the cost and time required in producing reliable and accurate results.
For more information about Sengenics, please visit our website at www.sengenics.com or email enquiries@sengenics.com
###
Contact
Sengenics
Johan Poole-Johnson
60192228429
www.sengenics.com
Johan Poole-Johnson
60192228429
www.sengenics.com
Contact
Categories